Geneos Therapeutics

[On Demand]
Geneos is a clinical stage biopharmaceutical company developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancer cells. We have developed a proprietary GT-EPIC(TM) platform to identify, design, manufacture, and deliver tumor specific treatments. The company has initiated 3 Phase Ib/IIa clinical programs in brain cancer and advanced liver cancer. All 3 INDs are open and recruiting patients.

The GT-EPIC(TM) platform is differentiated from other neoantigen approaches in 3 key ways making it cost effective, time efficient, and clinically efficacious:
1. Ability to drive CD8 and CD4 T cells (versus CD4 only)
2. Ability to deliver larger neoantigen payloads (50+ versus 5-20)
3. Faster manufacturing times (6-8 weeks versus 12-16 weeks)

Geneos is led by an experienced biopharma management team and advisors. The company has established clinical collaborations at major cancer centers including Johns Hopkins, Mt Sinai, and WUSM.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
GNOS-PV02 for the treatment of advanced hepatocellular cancer
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
President & CEO, Founder
Geneos Therapeutics, Inc.